Yes, you can prescribe ARNI at an eGFR of 27 mL/min/1.73 m²
ARNI (sacubitril/valsartan) can be safely initiated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), but you must start at half the usual starting dose. The FDA label explicitly addresses this scenario and provides clear dosing guidance 1.
Dosing Algorithm for eGFR 27
- Start at 24/26 mg twice daily (half the standard starting dose of 49/51 mg)
- Titrate upward every 2-4 weeks as tolerated
- Target the same final doses as patients with normal renal function
- Monitor potassium and creatinine closely, especially during titration
Supporting Evidence
FDA Label Guidance
The FDA-approved prescribing information specifically states: "In adults and pediatric patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m²), start sacubitril and valsartan tablets at half the usually recommended starting dose" 1. This is a clear regulatory endorsement for use in your patient's eGFR range.
Clinical Trial Data
The PARAGON-HF trial provides the strongest evidence that patients with lower eGFR actually derive MORE benefit from ARNI. In this large trial of 4,796 patients, those with eGFR ≤45 mL/min/1.73 m² showed the most pronounced treatment effect (RR 0.69,95% CI 0.51-0.94) for cardiovascular death and heart failure hospitalizations 2. The interaction analysis demonstrated greater benefit at lower eGFR levels (p=0.07 for continuous eGFR).
Safety Profile in Advanced CKD
Recent real-world evidence from 2025 demonstrates excellent safety in this population:
- A Japanese study of 30 patients with eGFR <30 mL/min/1.73 m² (mean 21.1 mL/min/1.73 m²) showed no cases of potassium >6.0 mmol/L and no cases of creatinine increase ≥30% after switching to ARNI 3
- A 2024 meta-analysis of 6,217 CKD patients found ARNI actually prevented Scr elevation (OR 0.79,95% CI 0.67-0.95) and reduced 50% eGFR decline events (OR 0.52,95% CI 0.32-0.84) 4
Renal Protection Benefits
ARNI appears to slow kidney function decline in advanced CKD. A 2026 study of 89 patients with mean baseline eGFR of 29 mL/min/1.73 m² showed the eGFR slope improved from -3.81 to -1.28 mL/min/1.73 m²/year after ARNI initiation—a difference of +2.52 mL/min/1.73 m²/year (p<0.001) 5. This suggests ARNI may actually be nephroprotective rather than nephrotoxic.
Monitoring Requirements
Close monitoring is essential but should not prevent initiation:
- Check potassium and creatinine at 1-2 weeks after initiation
- Recheck with each dose titration
- Monitor blood pressure (expect reduction of ~7 mmHg systolic) 3
- Watch for symptomatic hypotension (most common adverse effect)
Common Pitfalls to Avoid
- Don't withhold ARNI due to eGFR alone—the evidence shows safety and benefit at eGFR 27
- Don't forget the dose reduction—starting at full dose increases risk of hypotension and acute kidney injury
- Don't stop at the starting dose—titrate upward as tolerated to achieve mortality benefit
- Don't combine with ACE inhibitors—maintain 36-hour washout period 1
Guideline Support
The 2022 AHA/ACC/HFSA guidelines give ARNI a Class 1A recommendation for HFrEF patients with NYHA class II-III symptoms 6. While the guidelines recommend MRA use only when eGFR >30 mL/min/1.73 m², they make no such restriction for ARNI, and the FDA label explicitly permits use below this threshold with dose adjustment.
Bottom line: At eGFR 27, initiate ARNI at 24/26 mg twice daily, monitor closely, and titrate upward. The evidence supports both safety and enhanced benefit in this population.